Stage I and II meta-analysis of univariate Cox regression analysis results for the four associations in stage I and II
| ER-positive patients receiving endocrine treatment | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Chr:positiona | MAFb | HEBCS GWS HR (95% CI) | HEBCS GWS P | POSH GWS HR (95% CI) | POSH GWS P | POSH val. HR (95% CI) | POSH val. P | Success-A HR (95% CI) | Success-A P | Meta-analysis HR (95% CI) | Meta-analysis P | Location |
| rs8113308 | 19:52445386 | 0.152 | 1.72 (1.08–2.72) | 0.022 | 2.17 (1.37–3.45) | 9.81 × 10−4 | 1.45 (1.04–2.02) | 0.030 | 1.72 (1.11–2.68) | 0.015 | 1.69 (1.37–2.07) | 6.34 × 10−7 | ZNF613 |
| rs4082843 | 4:7109083 | 0.164 | 0,40 (0.23–0.67) | 6.50 × 10−4 | 0,36 (0.15–0.82) | 0.015 | 1,07 (0.75–1.51) | 0,484 | — | — | 0.72 (0.55–0.95) | 2.18 × 10−2 | GRPEL1 | SORCS2 |
| rs4767413 | 12:116951069 | 0.178 | 2,06 (1.41–3.01) | 1.90 × 10−4 | 1,67 (1.08–2.57) | 0.021 | 1,13 (0.82–1.56) | 0,328 | 1.07 (0.73–1.58) | 0.721 | 1.39 (1.15–1.67) | 5.86 × 10−4 | MED13L | LINC00173 |
| rs11085098 | 19:4784553 | 0.307 | 1,76 (1.25–2.47) | 0.001 | 1,61 (1.11–2.33) | 0.012 | 0,92 (0.69–1.22) | 0,242 | 0.83 (0.59–1.17) | 0.277 | 1.16 (0.99–1.37) | 7.02 × 10−2 | MIR7–3HG | FEM1A |
| ER-positive patients not receiving endocrine treatment | |||||||||||||
| SNP | Chr:positiona | MAFb | HEBCS GWS HR (95% CI) | HEBCS GWS P | POSH GWS HR (95% CI) | POSH GWS P | POSH val. HR (95% CI) | POSH val. P | Success-A HR (95% CI) | Success-A P | Meta-analysis HR (95% CI) | Meta-analysis P | Location |
| rs8113308 | 19:52445386 | 0.152 | 0.66 (0.40–1.07) | 0.093 | — | — | — | — | — | — | — | — | ZNF613 |
| rs4082843 | 4:7109083 | 0.164 | 1.15 (0.78–1.70 | 0,486 | — | — | — | — | — | — | — | — | GRPEL1 | SORCS2 |
| rs4767413 | 12:116951069 | 0.178 | 0.91 (0.56–1.48) | 0,712 | — | — | — | — | — | — | — | — | MED13L | LINC00173 |
| rs11085098 | 19:4784553 | 0.307 | 1.01 (0.70–1.46) | 0,963 | — | — | — | — | — | — | — | — | MIR7–3HG | FEM1A |
| ER-negative patients | |||||||||||||
| SNP | Chr:positiona | MAFb | HEBCS GWS HR (95% CI) | HEBCS GWS P | POSH GWS HR (95% CI) | POSH GWS P | POSH val. HR (95% CI) | POSH val. P | Success-A HR (95% CI) | Success-A P | Meta-analysis HR (95% CI) | Meta-analysis P | Location |
| rs8113308 | 19:52445386 | 0.152 | 0.65 (0.42–1.03) | 0.064 | 0.71 (0.46–1.09) | 0.121 | 0.93 (0.46–1.88) | 0.842 | 0.49 (0.26–0.93) | 0.029 | 0.71 (0.56–0.91) | 6.00 × 10−3 | ZNF613 |
| rs4082843 | 4:7109083 | 0.164 | 1,06 (0.73–1.52) | 0.765 | 1,00 (0.73–1.37) | 0.978 | 0,80 (0.38–1.67) | 0.346 | — | — | 1.00 (0.80–1.26) | 0.984 | GRPEL1 | SORCS2 |
| rs4767413 | 12:116951069 | 0.178 | 1,01 (0.64–1.61) | 0.958 | 1,04 (0.76–1.42) | 0.806 | 1,44 (0.80–2.58 | 0.148 | 0.98 (0.72–1.34) | 0.652 | 1.09 (0.89–1.33) | 0.400 | MED13L | LINC00173 |
| rs11085098 | 19:4784553 | 0.307 | 0,88 (0.64–1.21) | 0.428 | 1,00 (0.77–1.29) | 0.978 | 0,91 (0.56–1.47) | 0.460 | 1.09 (0.75–1.59) | 0.896 | 0.95 (0.81–1.12) | 0.544 | MIR7-3HG | FEM1A |
NOTE: The table presents per study as well as the meta-analysis results in ER-positive patients receiving endocrine treatment, ER-positive patients not receiving endocrine treatment, and ER-negative patients. The per study results in ER-positive patients not receiving endocrine treatment are only presented for HEBCS, because very few ER-positive patients did not receive endocrine treatment in POSH GWS, POSH validation, and SUCCESS-A. For SNPs rs4082843, there was no exact SNP match or a tag SNP with r2 > 0.8 available in SUCCESS-A data.